Insights into imaging · 2025
A radiomics-based model for predicting lymph nodes metastasis of pancreatic ductal adenocarcinoma: a multicenter study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhu Liwen, Zhao Ben, Xia Tianyi, Chang Di, Xia Cong, Liu Mengqiu, Li Ridong, Cao Buyue, Qiu Yue, Yu Yaoyao, Zhou Shuwei, Chen Huayu, Cai Wu, Ding Zhimin, Lu Chunqiang, Tang Tianyu, Song Yang, Wang Yuancheng, Ye Jing, Liu Ying, Ju Shenghong
Аннотация
PURPOSE: To develop a radiomics model to predict lymph nodes metastasis (LNM) in patients with pancreatic ductal adenocarcinoma (PDAC) and assess its value for clinical management.
METHODS: Patients with pathologically confirmed PDAC from four centers were retrospectively enrolled and split into four cohorts: training (n = 192), validation (n = 82), testing (n = 100), and clinical utilization (n = 163). A radiomics model was constructed based on contrast-enhanced CT (CECT) to predict LNM, and its performance was evaluated using the areas under the curve (AUC). Kaplan-Meier analysis was used to assess the prognostic and therapeutic decision-assisting value of the radiomics model.
RESULTS: A total of 437 patients (mean age: 63.1 years ± 9.2 standard deviation; 253 men) were included. The radiomics model outperformed other models with AUCs of 0.84, 0.82, and 0.78 in the training, validation, and testing cohorts (all p < 0.05), respectively. LNM predicted by the radiomics model was significantly associated with overall survival (p < 0.001). Kaplan-Meier analysis revealed that patients with a higher risk of LNM also had worse outcomes (all p < 0.05). Additionally, among the high-risk subgroup identified by the radiomics model in the clinical utilization cohort, patients who underwent dissection of ≥ 15 lymph nodes exhibited better overall survival compared to those with fewer lymph nodes dissected (p = 0.002).
CONCLUSION: The radiomics model we constructed demonstrated impressive performance in predicting LNM and prognosis, suggesting its potential for optimizing the clinical management of PDAC.
CRITICAL RELEVANCE STATEMENT: This radiomics model can predict the risk of lymph nodes metastasis and prognosis of patients in pancreatic ductal adenocarcinoma and has potential value in selecting patients who can benefit from different extents of lymph nodes dissection.
KEY POINTS: Thorough lymph node dissection is important for achieving the best prognosis in pancreatic ductal adenocarcinoma (PDAC). The radiomics model can accurately predict lymph node status and stratify patients' prognosis. This radiomics model enhances the clinical management of PDAC.
METHODS: Patients with pathologically confirmed PDAC from four centers were retrospectively enrolled and split into four cohorts: training (n = 192), validation (n = 82), testing (n = 100), and clinical utilization (n = 163). A radiomics model was constructed based on contrast-enhanced CT (CECT) to predict LNM, and its performance was evaluated using the areas under the curve (AUC). Kaplan-Meier analysis was used to assess the prognostic and therapeutic decision-assisting value of the radiomics model.
RESULTS: A total of 437 patients (mean age: 63.1 years ± 9.2 standard deviation; 253 men) were included. The radiomics model outperformed other models with AUCs of 0.84, 0.82, and 0.78 in the training, validation, and testing cohorts (all p < 0.05), respectively. LNM predicted by the radiomics model was significantly associated with overall survival (p < 0.001). Kaplan-Meier analysis revealed that patients with a higher risk of LNM also had worse outcomes (all p < 0.05). Additionally, among the high-risk subgroup identified by the radiomics model in the clinical utilization cohort, patients who underwent dissection of ≥ 15 lymph nodes exhibited better overall survival compared to those with fewer lymph nodes dissected (p = 0.002).
CONCLUSION: The radiomics model we constructed demonstrated impressive performance in predicting LNM and prognosis, suggesting its potential for optimizing the clinical management of PDAC.
CRITICAL RELEVANCE STATEMENT: This radiomics model can predict the risk of lymph nodes metastasis and prognosis of patients in pancreatic ductal adenocarcinoma and has potential value in selecting patients who can benefit from different extents of lymph nodes dissection.
KEY POINTS: Thorough lymph node dissection is important for achieving the best prognosis in pancreatic ductal adenocarcinoma (PDAC). The radiomics model can accurately predict lymph node status and stratify patients' prognosis. This radiomics model enhances the clinical management of PDAC.